Stories

The drug companies impeding access to generics

The FDA headquarters in Maryland.
The FDA is calling out brand-name drug makers. Photo: Al Drago/CQ Roll Call via Getty Images

The Food and Drug Administration published a list Thursday showing pharmaceutical companies that the agency said could be using "gaming tactics" to delay generic competition with their brand-name drugs. Many drugs on the list, like Revlimid and H.P. Acthar Gel, have high price tags.

The bottom line: It's a big deal for the Trump administration to publicly shame drug companies for limiting access to their costly brand-name products. But the big question is whether this move, along with other policies, will make it easier for lower-cost generics to hit the market.